1
|
Extracellular Vesicles as Drivers of Immunoinflammation in Atherothrombosis. Cells 2022; 11:cells11111845. [PMID: 35681540 PMCID: PMC9180657 DOI: 10.3390/cells11111845] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 05/30/2022] [Accepted: 06/01/2022] [Indexed: 02/07/2023] Open
Abstract
Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality all over the world. Extracellular vesicles (EVs), small lipid-bilayer membrane vesicles released by most cellular types, exert pivotal and multifaceted roles in physiology and disease. Emerging evidence emphasizes the importance of EVs in intercellular communication processes with key effects on cell survival, endothelial homeostasis, inflammation, neoangiogenesis, and thrombosis. This review focuses on EVs as effective signaling molecules able to both derail vascular homeostasis and induce vascular dysfunction, inflammation, plaque progression, and thrombus formation as well as drive anti-inflammation, vascular repair, and atheroprotection. We provide a comprehensive and updated summary of the role of EVs in the development or regression of atherosclerotic lesions, highlighting the link between thrombosis and inflammation. Importantly, we also critically describe their potential clinical use as disease biomarkers or therapeutic agents in atherothrombosis.
Collapse
|
2
|
Zifkos K, Dubois C, Schäfer K. Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence. Int J Mol Sci 2021; 22:ijms22179317. [PMID: 34502228 PMCID: PMC8431093 DOI: 10.3390/ijms22179317] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 08/24/2021] [Accepted: 08/25/2021] [Indexed: 12/16/2022] Open
Abstract
Extracellular vesicles (EVs) compose a heterogenous group of membrane-derived particles, including exosomes, microvesicles and apoptotic bodies, which are released into the extracellular environment in response to proinflammatory or proapoptotic stimuli. From earlier studies suggesting that EV shedding constitutes a cellular clearance mechanism, it has become evident that EV formation, secretion and uptake represent important mechanisms of intercellular communication and exchange of a wide variety of molecules, with relevance in both physiological and pathological situations. The putative role of EVs in hemostasis and thrombosis is supported by clinical and experimental studies unraveling how these cell-derived structures affect clot formation (and resolution). From those studies, it has become clear that the prothrombotic effects of EVs are not restricted to the exposure of tissue factor (TF) and phosphatidylserines (PS), but also involve multiplication of procoagulant surfaces, cross-linking of different cellular players at the site of injury and transfer of activation signals to other cell types. Here, we summarize the existing and novel clinical and experimental evidence on the role and function of EVs during arterial and venous thrombus formation and how they may be used as biomarkers as well as therapeutic vectors.
Collapse
Affiliation(s)
- Konstantinos Zifkos
- Center for Thrombosis and Hemostasis, University Medical Center Mainz, D-55131 Mainz, Germany;
| | - Christophe Dubois
- Aix Marseille University, INSERM 1263, Institut National de la Recherche pour l’Agriculture, l’alimentation et l’Environnement (INRAE) 1260, Center for CardioVascular and Nutrition Research (C2VN), F-13380 Marseille, France;
| | - Katrin Schäfer
- Department of Cardiology, Cardiology I, University Medical Center Mainz, D-55131 Mainz, Germany
- Correspondence:
| |
Collapse
|
3
|
Persistent circulating platelet and endothelial derived microparticle signature may explain on-going pro-thrombogenicity after acute coronary syndrome. Thromb Res 2021; 206:60-65. [PMID: 34418680 DOI: 10.1016/j.thromres.2021.07.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 07/02/2021] [Accepted: 07/31/2021] [Indexed: 11/23/2022]
Abstract
AIMS Microparticles (MPs) are submicron vesicles, released from activated, and apoptotic cells. MPs are elevated in the circulation of patients with coronary artery disease (CAD) and have pro-thrombotic potential. However, limited data exists on MP signature over time following an acute coronary event. METHODS & RESULTS Circulating total annexin v + (Anv+) MPs of endothelial (EMP), platelet (PMP), monocyte (MMP), neutrophil (NMP) and smooth muscle cell (SMMP) origin were quantified by flow cytometry. 13 patients with acute coronary syndrome (ACS) were prospectively enrolled and 12 patients with stable angina (SA) were included as a comparator group. A panel of MP was measured at baseline, after percutaneous coronary intervention (PCI) and at days 1, 7, 30 and 6 months. Intra & inter group comparison was made between various time points. MP mediated thrombin generation was measured by recording lag phase, velocity index, peak thrombin and endogenous thrombin potential at these time points and compared with healthy controls. The total AnV+ MP levels were similar in ACS and SA groups at baseline, peaked immediately after PCI and were at their lowest on day 1. PMP & EMP levels remained significantly elevated in ACS patients at 6 months when compared to SA. No such difference was noted with NMP, MMP and SMMP. Patients with coronary artery disease showed abnormal thrombograms when compared to controls. Peak thrombin (nano moles) was significantly higher in CAD when compared to controls (254 IQR [226, 239] in ACS, 255 IQR [219, 328] in SA and 132 IQR [57, 252] in controls; p = 0.006). Differences in thrombin generation between ACS and SA were not significant (p = 1). Furthermore, thrombin parameters remained abnormal in ACS & SA patients at 6 months. CONCLUSIONS Total MP and individual MP phenotypes were significantly elevated after PCI reflecting endothelial injury. Elevated PMP and EMP levels at 6 months in ACS patients is suggestive of on-going inflammation, endothelial injury and may explain on-going pro-thrombogenicity seen up to 6 months after ACS despite dual antiplatelet therapy.
Collapse
|
4
|
Weisel JW, Litvinov RI. Visualizing thrombosis to improve thrombus resolution. Res Pract Thromb Haemost 2021; 5:38-50. [PMID: 33537528 PMCID: PMC7845077 DOI: 10.1002/rth2.12469] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 11/05/2020] [Accepted: 11/15/2020] [Indexed: 12/12/2022] Open
Abstract
The severity, course, and outcomes of thrombosis are determined mainly by the size and location of the thrombus, but studying thrombus structure and composition has been an important but challenging task. The substantial progress in determination of thrombus morphology has become possible due to new intravital imaging methodologies in combination with mechanical thrombectomy, which allows extraction of a fresh thrombus from a patient followed by microscopy. Thrombi have been found to contain various structural forms of fibrin along with platelet aggregates, leukocytes, and red blood cells, many of which acquire a polyhedral shape (polyhedrocytes) as a result of intravital platelet-driven contraction. The relative volume fractions of thrombus components and their structural forms vary substantially, depending on the clinical and pathogenic characteristics. This review summarizes recent research that describes quantitative and qualitative morphologic characteristics of arterial and venous thrombi that are relevant for the pathogenesis, prophylaxis, diagnosis, and treatment of thrombosis.
Collapse
Affiliation(s)
- John W. Weisel
- Department of Cell and Developmental BiologyUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaPAUSA
| | - Rustem I. Litvinov
- Department of Cell and Developmental BiologyUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaPAUSA
| |
Collapse
|
5
|
Zacharia E, Zacharias K, Papamikroulis GA, Bertsias D, Miliou A, Pallantza Z, Papageorgiou N, Tousoulis D. Cell-Derived Microparticles and Acute Coronary Syndromes: Is there a Predictive Role for Microparticles? Curr Med Chem 2020; 27:4440-4468. [DOI: 10.2174/0929867327666191213104841] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 09/09/2019] [Accepted: 11/22/2019] [Indexed: 12/21/2022]
Abstract
Background:Despite the recent advances in the treatment of Acute Coronary Syndromes (ACS), patients with ACS are still exposed to an increased risk for adverse cardiovascular events, while their prognosis is difficult to determine. Experimental and clinical studies have shown that cell-derived Microparticles (MPs) are associated with the underlying pathophysiological processes that are responsible for atherogenesis and may be causally implicated in the induction of atherothrombosis.Objective:In the present article, we aimed to review the available evidence regarding the predictive role of MPs in patients with ACS.Results:Evidence suggests that endothelial MPs are associated with future adverse cardiovascular events in patients with ACS. Platelet-derived MPs have been excessively studied, since they have been found to trigger the coagulation cascade; however, their role as predictors of future cardiovascular events remains debatable. The role of red blood cell-derived MPs is more intriguing; they have been proposed as markers of ongoing thrombosis in patients with ACS, while previous studies have shown that they have anti-coagulant properties in healthy individuals. Leukocyte-derived MPs may also have a predictive role, although the studies regarding these are still limited. Last but not least, it was an interesting discovery that circulating MPs can provide information regarding the angiographic lesions in patients with ACS.Conclusion:The concept of MPs as potential circulating biomarkers in patients with ACS holds much promise. However, large-scale clinical studies are required to evaluate whether the measurement of plasma MPs could be of clinical significance and, thus, dictate a more aggressive treatment strategy in patients with high levels of circulating MPs.
Collapse
Affiliation(s)
- Effimia Zacharia
- 1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece
| | | | | | | | - Antigoni Miliou
- 1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece
| | - Zoi Pallantza
- 1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece
| | | | - Dimitris Tousoulis
- 1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece
| |
Collapse
|
6
|
Zhou B, Du Y, Xue Y, Miao G, Wei T, Zhang P. Identification of Malonylation, Succinylation, and Glutarylation in Serum Proteins of Acute Myocardial Infarction Patients. Proteomics Clin Appl 2019; 14:e1900103. [PMID: 31532912 DOI: 10.1002/prca.201900103] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 08/21/2019] [Indexed: 11/09/2022]
Abstract
PURPOSE To identify protein malonylation, succinylation, and glutarylation in human and rat serum. EXPERIMENTAL DESIGN Immunoprecipitation coupled with MS/MS is employed to compare the relative abundance of malonylation, succinylation, and glutarylation of serum protein in acute myocardial infarction human and rat. RESULTS One hundred thirty and 48 unique malonylated, succinylated, or glutarylated peptides are found in human and rat serum, respectively. Succinylation is the most predominant modification. The most modified protein is albumin. Abundance of serum protein succinylation and glutarylation is significantly (p < 0.05) lower in the peripheral serum of ST-segment elevation myocardial infarction patients compared with healthy volunteers, which is also observed in acute myocardial infarction rats. CONCLUSIONS AND CLINICAL RELEVANCE Malonylation, succinylation, and glutarylation widely exist in mammalian serum proteins, and may reveal novel mechanism of acute myocardial infarction.
Collapse
Affiliation(s)
- Boda Zhou
- Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine Tsinghua University, Beijing, 102218, China
| | - Yipeng Du
- National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
| | - Yajun Xue
- Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine Tsinghua University, Beijing, 102218, China
| | - Guobin Miao
- Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine Tsinghua University, Beijing, 102218, China
| | - Taotao Wei
- National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
| | - Ping Zhang
- Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine Tsinghua University, Beijing, 102218, China
| |
Collapse
|
7
|
Geng XY, Xiao N, Han Y, Li YJ. Platelet Microparticles: A Tool to Predict Infarction Area in Rats. J INVEST SURG 2019; 34:64-69. [PMID: 31109212 DOI: 10.1080/08941939.2019.1606369] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Background: Whether there is a quantitative correlation between platelet microparticles (PMPs)/calpain and infarction area is still unclear. Whether present antiplatelet agents can improve myocardial infarction by influencing PMPs need to be revealed. The object of our study was to answer those questions. Methods: Male Wistar rats were used for all studies. All rats were randomly divided into five groups: sham-operated group, myocardial infarction group (blank control group), aspirin intervention group, aspirin combined with clopidogrel intervention group, and aspirin combined with ticagrelor intervention group. Venous blood and hearts were collected at day 7 following MI. ELISA was applied to detect PMPs level. Infarction size was determined by TTC staining method. The comparisons of multiple means were tested with analysis of variance. And the two-two comparisons among the means were done by Student-Newman-Keuls and LSD method. Results: PMPs level and infarction area did not differ between aspirin combined with clopidogrel intervention group and aspirin combined with ticagrelor intervention group. However, significant differences were detected between any two other groups. PMPs were decreased more in dual antiplatelet intervention group. Pearson correlation analysis showed a strong correlation between PMPs and infarction area (r = 0.90) as well as calpain 10 and infarction area (r = 0.84). We created a regression model: y = 4.61 + 0.28*x (y: infarction area, x: PMPs) to assess myocardial infarction area by PMPs level. Conclusions: Antiplatelet agents may decrease infarction areas by modifying PMPs. There was a strong correlation between PMPs and infarction area. Therefore, PMPs could be used as a tool to assess infarction area.
Collapse
Affiliation(s)
- Xiao-Yong Geng
- Department of Cardiology, The Third Hospital of Hebei Medical University, Shijiazhuang, China
| | - Na Xiao
- Department of Cardiology, The Third Hospital of Hebei Medical University, Shijiazhuang, China
| | - Yu Han
- Department of Cardiology, The Third Hospital of Hebei Medical University, Shijiazhuang, China
| | - Yong-Jun Li
- Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
8
|
Osman J, Tan SC, Lee PY, Low TY, Jamal R. Sudden Cardiac Death (SCD) - risk stratification and prediction with molecular biomarkers. J Biomed Sci 2019; 26:39. [PMID: 31118017 PMCID: PMC6530025 DOI: 10.1186/s12929-019-0535-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Accepted: 05/16/2019] [Indexed: 12/15/2022] Open
Abstract
Sudden cardiac death (SCD) is a sudden, unexpected death that is caused by the loss of heart function. While SCD affects many patients suffering from coronary artery diseases (CAD) and heart failure (HF), a considerable number of SCD events occur in asymptomatic individuals. Certain risk factors for SCD have been identified and incorporated in different clinical scores, however, risk stratification using such algorithms is only useful for health management rather than for early detection and prediction of future SCD events in high-risk individuals. In this review, we discuss different molecular biomarkers that are used for early detection of SCD. This includes genetic biomarkers, where the majority of them are genomic variants for genes that encode for ion channels. Meanwhile, protein biomarkers often denote proteins that play roles in pathophysiological processes that lead to CAD and HF, notably (i) atherosclerosis that involves oxidative stress and inflammation, as well as (ii) cardiac tissue damage that involves neurohormonal and hemodynamic regulation and myocardial stress. Finally, we outline existing challenges and future directions including the use of OMICS strategy for biomarker discovery and the multimarker panels.
Collapse
Affiliation(s)
- Junaida Osman
- UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - Shing Cheng Tan
- UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - Pey Yee Lee
- UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - Teck Yew Low
- UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
| | - Rahman Jamal
- UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| |
Collapse
|
9
|
Shan X, Liu Z, Wulasihan M, Ma S. Edoxaban improves atrial fibrillation and thromboembolism through regulation of the Wnt-β-induced PI3K/ATK-activated protein C system. Exp Ther Med 2019; 17:3509-3517. [PMID: 30988731 PMCID: PMC6447810 DOI: 10.3892/etm.2019.7379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Accepted: 04/20/2018] [Indexed: 11/24/2022] Open
Abstract
Thromboembolism is a commonly observed condition in geriatrics that is caused by vascular endothelial injury, platelet activation, physiological coagulation processes, reduction of anticoagulant activity, decreased fibrinolytic activity and abnormal flow in the heart chamber, artery or vein. The protein C anticoagulant system serves a crucial role in anticoagulant therapy for the treatment of thromboembolism. Previous findings have suggested that edoxaban is an efficient oral anticoagulant in the acute treatment of venous thromboembolism. In the present study, the efficacy of edoxaban on thromboembolism induced by atrial fibrillation was investigated in a mouse model. Inflammatory factors interleukin (IL)-1, −4, −8 and tumor necrosis factor (TNF)-α were analyzed in the sera of mice with fibrillation induced by thromboembolism. Expression and activity of thymic stromal lymphopoietin (TSLP) and activated protein C resistance were investigated in platelets and vascular endothelial cells (VECs). TSLP-induced platelet viability, Wnt-β phosphorylation and integrin expression were analyzed in platelets. Furthermore, Wnt-β expression and the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in VECs were analyzed. Results demonstrated that the expression levels of IL-1, −4, −8 and TNF-α were significantly downregulated in the sera of mice with fibrillation and thromboembolism following treatment with edoxaban (P<0.01). Furthermore, the expression levels of prostacyclin (PGI2), prostaglandin (PG)E2, PGD2 and PGF2α were significantly increased in the sera of experimental mice that received edoxaban therapy (P<0.01). Results also indicated that edoxaban significantly stimulated the protein expression of TSLP and activated Wnt-β phosphorylation and integrin expression in platelets (P<0.01). In addition, edoxaban therapy significantly upregulated the expression levels of PI3K and AKT, and subsequently increased the activity of protein C and S in VECs (P<0.01). Notably, edoxaban treatment improved atrial fibrillation and thromboembolism, as determined by pathological analysis. In conclusion, these results suggested that edoxaban elicited beneficial effects for mice with atrial fibrillation induced by thromboembolism through the regulation of the Wnt-β-induced PI3K/ATK-activated protein C system.
Collapse
Affiliation(s)
- Xuefeng Shan
- Department of Pediatric Surgery, The First Affiliated Hospital, Xinjiang Medical University, Urumchi, Xinjiang 830054, P.R. China
| | - Zhiqiang Liu
- Comprehensive Heart Internal Medicine, Heart Center of The First Affiliated Hospital, Xinjiang Medical University, Urumchi, Xinjiang 830054, P.R. China
| | - Muhuyati Wulasihan
- Comprehensive Heart Internal Medicine, Heart Center of The First Affiliated Hospital, Xinjiang Medical University, Urumchi, Xinjiang 830054, P.R. China
| | - Songfeng Ma
- Department of Pediatric Surgery, The First Affiliated Hospital, Xinjiang Medical University, Urumchi, Xinjiang 830054, P.R. China
| |
Collapse
|
10
|
Effects of Microvesicles on Cell Apoptosis under Hypoxia. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2019; 2019:5972152. [PMID: 31178970 PMCID: PMC6501227 DOI: 10.1155/2019/5972152] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 02/19/2019] [Indexed: 12/21/2022]
Abstract
Hypoxia, as one of the severe cellular stresses, can cause cellular injury and even cell death. Apoptosis is the main mechanism of regulating cell death and is closely related to the cell death caused by hypoxia. However, hypoxia-induced apoptosis is not entirely the result of direct hypoxic stimulus of cells. In recent years, it has been found that cells injured by hypoxia can shed a kind of membranous vesicles, which are called microvesicles (MVs). MVs can carry bioactive molecules from injured mother cells and appear in blood, cerebrospinal fluid, and other body fluids. MVs can induce normal cell apoptosis by transferring bioactive molecules into adjacent cells and amplifying the hypoxic injury in an organism. This review summarizes the characteristic changes of MVs derived from hypoxic cells and the mechanism of normal cell apoptosis mediated by hypoxic cell-derived MVs. Finally, we introduce the significance of this apoptosis-apoptosis cascade reaction in hypoxic diseases.
Collapse
|
11
|
Bacha NC, Levy M, Guerin CL, Le Bonniec B, Harroche A, Szezepanski I, Renard JM, Gaussem P, Israel-Biet D, Boulanger CM, Smadja DM. Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension. Pediatr Pulmonol 2019; 54:66-72. [PMID: 30485728 DOI: 10.1002/ppul.24190] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 10/12/2018] [Indexed: 11/09/2022]
Abstract
BACKGROUND Pulmonary arterial hypertension (PAH) results from pulmonary vascular disease and may eventually lead to right heart failure and death. Vasodilator therapy has greatly improved PAH prognosis. Circulating microvesicles are considered as surrogate markers of endothelial and hematopoietic cell activation. AIM Thus, our purpose was to determine if MVs are upregulated in pediatric PAH such as reported in adult patients, and to analyze the impact of vasodilator therapies on MV count and function. PATIENTS Population study consisted of 26 patients of median age 6.09 years, with Congenital Heart Disease (CHD) and elevated pulmonary vascular resistance (CHD-PAH) or idiopathic PAH (iPAH). RESULTS Compared to healthy controls, all circulating MV subpopulations were found higher in untreated PAH patients. No significant differences of annexin-V+ total MV, endothelial, or leukocyte derived-MV counts were found between untreated patients and those receiving oral vasodilator therapies. Conversely, platelet MVs were significantly lower in the group treated with SC-treprostinil compared with both untreated PAH and oral therapy groups (P = 0.01), and exhibited a significant decrease of phospholipid procoagulant activity. Control samples treated in vitro with treprostinil at therapeutic concentrations showed as expected a significant decrease of platelet aggregation but also a reduced spontaneous MV generation. CONCLUSION Our results suggest that treprostinil, besides vasodilation, might exert its beneficial effect through an inhibition of platelet activation, resulting in a decreased number and procoagulant activity of circulating MVs.
Collapse
Affiliation(s)
- Nour C Bacha
- Inserm UMR-S1140, Paris, France.,Université Paris Descartes, Sorbonne Paris Cite, Paris, France
| | - Marilyne Levy
- Inserm UMR-S1140, Paris, France.,AP-HP, Necker Hospital, M3C-Unité Médico-Chirugicale de Cardiologie Pédiatrique, Paris, France
| | - Coralie L Guerin
- Inserm UMR-S1140, Paris, France.,Université Paris Descartes, Sorbonne Paris Cite, Paris, France.,Institut Curie, Paris, France
| | - Bernard Le Bonniec
- Inserm UMR-S1140, Paris, France.,Université Paris Descartes, Sorbonne Paris Cite, Paris, France
| | - Annie Harroche
- AP-HP, Necker Hospital, Hematology Department, Paris, France
| | - Isabelle Szezepanski
- AP-HP, Necker Hospital, M3C-Unité Médico-Chirugicale de Cardiologie Pédiatrique, Paris, France
| | - Jean M Renard
- Université Paris Descartes, Sorbonne Paris Cite, Paris, France.,Inserm UMR-S970, PARCC, Paris, France
| | - Pascale Gaussem
- Inserm UMR-S1140, Paris, France.,Université Paris Descartes, Sorbonne Paris Cite, Paris, France.,AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France
| | - Dominique Israel-Biet
- Inserm UMR-S1140, Paris, France.,Université Paris Descartes, Sorbonne Paris Cite, Paris, France.,AP-HP, European Hospital Georges Pompidou, Pneumology Department, Paris, France
| | - Chantal M Boulanger
- Université Paris Descartes, Sorbonne Paris Cite, Paris, France.,Inserm UMR-S970, PARCC, Paris, France
| | - David M Smadja
- Inserm UMR-S1140, Paris, France.,Université Paris Descartes, Sorbonne Paris Cite, Paris, France.,AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France
| |
Collapse
|
12
|
Bacha NC, Blandinieres A, Rossi E, Gendron N, Nevo N, Lecourt S, Guerin CL, Renard JM, Gaussem P, Angles-Cano E, Boulanger CM, Israel-Biet D, Smadja DM. Endothelial Microparticles are Associated to Pathogenesis of Idiopathic Pulmonary Fibrosis. Stem Cell Rev Rep 2018; 14:223-235. [PMID: 29101610 DOI: 10.1007/s12015-017-9778-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by obliteration of alveolar architecture, resulting in declining lung function and ultimately death. Pathogenic mechanisms remain unclear but involve a concomitant accumulation of scar tissue together with myofibroblasts activation. Microparticles (MPs) have been investigated in several human lung diseases as possible pathogenic elements, prognosis markers and therapeutic targets. We postulated that levels and cellular origins of circulating MPs might serve as biomarkers in IPF patients and/or as active players of fibrogenesis. Flow cytometry analysis showed a higher level of Annexin-V positive endothelial and platelet MPs in 41 IPF patients compared to 22 healthy volunteers. Moreover, in IPF patients with a low diffusing capacity of the lung for carbon monoxide (DLCO<40%), endothelial MPs (EMPs) were found significantly higher compared to those with DLCO>40% (p = 0.02). We then used EMPs isolated from endothelial progenitor cells (ECFCs) extracted from IPF patients or controls to modulate normal human lung fibroblast (NHLF) properties. We showed that EMPs did not modify proliferation, collagen deposition and myofibroblast transdifferentiation. However, EMPs from IPF patients stimulated migration capacity of NHLF. We hypothesized that this effect could result from EMPs fibrinolytic properties and found indeed higher plasminogen activation potential in total circulating MPs and ECFCs derived MPs issued from IPF patients compared to those isolated from healthy controls MPs. Our study showed that IPF is associated with an increased level of EMPs in the most severe patients, highlighting an active process of endothelial activation in the latter. Endothelial microparticles might contribute to the lung fibroblast invasion mediated, at least in part, by a fibrinolytic activity.
Collapse
Affiliation(s)
- Nour C Bacha
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France
| | - Adeline Blandinieres
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France.,Hematology Department and UMR-S1140, AP-HP, European Hospital Georges Pompidou, 20 rue Leblanc, 75015, Paris, France
| | - Elisa Rossi
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France
| | - Nicolas Gendron
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France.,Hematology Department and UMR-S1140, AP-HP, European Hospital Georges Pompidou, 20 rue Leblanc, 75015, Paris, France
| | - Nathalie Nevo
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France
| | | | - Coralie L Guerin
- National Cytometry Platform, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg, France
| | - Jean Marie Renard
- Sorbonne Paris Cite, Université Paris Descartes, Paris, France.,Inserm UMR-S970, PARCC, Paris, France
| | - Pascale Gaussem
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France.,Hematology Department and UMR-S1140, AP-HP, European Hospital Georges Pompidou, 20 rue Leblanc, 75015, Paris, France
| | - Eduardo Angles-Cano
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France
| | - Chantal M Boulanger
- Sorbonne Paris Cite, Université Paris Descartes, Paris, France.,Inserm UMR-S970, PARCC, Paris, France
| | - Dominique Israel-Biet
- Inserm UMR-S1140, Paris, France.,Sorbonne Paris Cite, Université Paris Descartes, Paris, France.,Pneumology Department, AP-HP, European Hospital Georges Pompidou, Paris, France
| | - David M Smadja
- Inserm UMR-S1140, Paris, France. .,Sorbonne Paris Cite, Université Paris Descartes, Paris, France. .,Hematology Department and UMR-S1140, AP-HP, European Hospital Georges Pompidou, 20 rue Leblanc, 75015, Paris, France.
| |
Collapse
|
13
|
Li Q, Liu X, Chang M, Lu Z. Thrombolysis Enhancing by Magnetic Manipulation of Fe₃O₄ Nanoparticles. MATERIALS (BASEL, SWITZERLAND) 2018; 11:E2313. [PMID: 30453656 PMCID: PMC6265696 DOI: 10.3390/ma11112313] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 11/12/2018] [Accepted: 11/12/2018] [Indexed: 12/17/2022]
Abstract
In this paper, an effective method of accelerating urokinase-administrated thrombolysis through a rotating magnetic field (RMF) of guided magnetic nanoparticles (NPs) in the presence of low-dose urokinase is proposed. The dispersed Fe₃O₄ NPs mixed with urokinase were injected into microfluidic channels occluded by thrombus prepared in vitro. These magnetic NPs aggregated into elongated clusters under a static magnetic field, and were then driven by the RMF. The rotation of Fe₃O₄ aggregates produced a vortex to enhance the diffusion of urokinase to the surface of the thrombus and accelerate its dissolution. A theoretical model based on convective diffusion was constructed to describe the thrombolysis mechanism. The thrombus lysis speed was determined according to the change of the thrombus dissolution length with time in the microfluidic channel. The experimental results showed that the thrombolysis speed with rotating magnetic NPs is significantly increased by nearly two times compared with using the same dose of pure urokinase. This means that the magnetically-controlled NPs approach provides a feasible way to achieve a high thrombolytic rate with low-dose urokinase in use.
Collapse
Affiliation(s)
- Qian Li
- The State Key Laboratory of Digital Manufacturing Equipment and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
| | - Xiaojun Liu
- The State Key Laboratory of Digital Manufacturing Equipment and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
| | - Ming Chang
- Department of Mechanical Engineering, Chung Yuan Christian University, Chung Li 32023, Taiwan.
- College of Mechanical Engineering and Automation, Huaqiao University, Xiamen 361021, Fujian, China.
| | - Zhen Lu
- School of Economics and Management, Shanghai University of Electric Power, Shanghai 200090, China.
| |
Collapse
|
14
|
Spaulding C, Karam N. [Sudden cardiac death and coronary thrombus]. Ann Cardiol Angeiol (Paris) 2017; 66:400-404. [PMID: 29106829 DOI: 10.1016/j.ancard.2017.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Out-of-hospital cardiac arrest is most often due to an acute coronary artery occlusion. The cause of coronary thrombosis in cardiac arrest is debated. Plaque erosion could be a trigger leading to immediate thrombus formation followed by ventricular fibrillation or rapid ventricular tachycardia. Coronary artery spasm is frequent: spasm provocation tests should be performed in survivors with normal coronary arteries. Use of drugs such as cocaine can lead to sudden death and blood sampling at arrival is recommended in survivors of out-of-hospital cardiac arrest. Delivery of immediate and effective basic life support remains the most important predictive factor for survival in out-of-hospital cardiac arrest.
Collapse
Affiliation(s)
- C Spaulding
- Département de cardiologie, hôpital européen Georges-Pompidou, Inserm U 909, centre d'expertise de la mort subite, université Paris-Descartes, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France.
| | - N Karam
- Département de cardiologie, hôpital européen Georges-Pompidou, Inserm U 909, centre d'expertise de la mort subite, université Paris-Descartes, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France
| |
Collapse
|
15
|
Özdamar Ü, Akboğa MK, Bayraktar MF, Özeke Ö. New Insights on the "DC Shock-Reperfusion" in ST Elevation Myocardial Infarction: Killing Two Birds with One Stone? Balkan Med J 2017; 34:382-383. [PMID: 28783027 PMCID: PMC5615975 DOI: 10.4274/balkanmedj.2016.0447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- Ümran Özdamar
- Clinic of Cardiology, Türkiye Yüksek İhtisas Training and Research Hospital, Ankara, Turkey
| | - Mehmet Kadri Akboğa
- Clinic of Cardiology, Türkiye Yüksek İhtisas Training and Research Hospital, Ankara, Turkey
| | | | - Özcan Özeke
- Clinic of Cardiology, Türkiye Yüksek İhtisas Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
16
|
Ridger VC, Boulanger CM, Angelillo-Scherrer A, Badimon L, Blanc-Brude O, Bochaton-Piallat ML, Boilard E, Buzas EI, Caporali A, Dignat-George F, Evans PC, Lacroix R, Lutgens E, Ketelhuth DFJ, Nieuwland R, Toti F, Tunon J, Weber C, Hoefer IE. Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Thromb Haemost 2017; 117:1296-1316. [PMID: 28569921 DOI: 10.1160/th16-12-0943] [Citation(s) in RCA: 167] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 04/27/2017] [Indexed: 12/15/2022]
Abstract
Microvesicles are members of the family of extracellular vesicles shed from the plasma membrane of activated or apoptotic cells. Microvesicles were initially characterised by their pro-coagulant activity and described as "microparticles". There is mounting evidence revealing a role for microvesicles in intercellular communication, with particular relevance to hemostasis and vascular biology. Coupled with this, the potential of microvesicles as meaningful biomarkers is under intense investigation. This Position Paper will summarise the current knowledge on the mechanisms of formation and composition of microvesicles of endothelial, platelet, red blood cell and leukocyte origin. This paper will also review and discuss the different methods used for their analysis and quantification, will underline the potential biological roles of these vesicles with respect to vascular homeostasis and thrombosis and define important themes for future research.
Collapse
Affiliation(s)
| | - Chantal M Boulanger
- Victoria Ridger, PhD, Department of Infection, Immunity and Cardiovascular Disease, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK, E-mail: , or, Chantal M. Boulanger, PhD, INSERM UMR-S 970, Paris Cardiovascular Research Center - PARCC, 56 rue Leblanc, 75015 Paris, France, E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Heart failure (HF) continues to have a sufficient impact on morbidity, mortality, and disability in developed countries. Growing evidence supports the hypothesis that microparticles (MPs) might contribute to the pathogenesis of the HF development playing a pivotal role in the regulation of the endogenous repair system, thrombosis, coagulation, inflammation, immunity, and metabolic memory phenomenon. Therefore, there is a large body of data clarifying the predictive value of MP numerous in circulation among subjects with HF. Although the determination of MP signature is better than measurement of single MP circulating level, there is not yet close confirmation that immune phenotype of cells produced MPs are important for HF prediction and development. The aim of the chapter is to summarize knowledge regarding the role of various MPs in diagnosis and prognosis of HF. The role of MPs as a delivery vehicle for drugs attenuated cardiac remodeling is considered.
Collapse
|
18
|
Karam N, Bataille S, Marijon E, Giovannetti O, Tafflet M, Savary D, Benamer H, Caussin C, Garot P, Juliard JM, Pires V, Boche T, Dupas F, Le Bail G, Lamhaut L, Laborne F, Lefort H, Mapouata M, Lapostolle F, Spaulding C, Empana JP, Jouven X, Lambert Y. Identifying Patients at Risk for Prehospital Sudden Cardiac Arrest at the Early Phase of Myocardial Infarction. Circulation 2016; 134:2074-2083. [DOI: 10.1161/circulationaha.116.022954] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Accepted: 09/28/2016] [Indexed: 11/16/2022]
Abstract
Background:
In-hospital mortality of ST-segment–elevation myocardial infarction (STEMI) has decreased drastically. In contrast, prehospital mortality from sudden cardiac arrest (SCA) remains high and difficult to reduce. Identification of the patients with STEMI at higher risk for prehospital SCA could facilitate rapid triage and intervention in the field.
Methods:
Using a prospective, population-based study evaluating all patients with STEMI managed by emergency medical services in the greater Paris area (11.7 million inhabitants) between 2006 and 2010, we identified characteristics associated with an increased risk of prehospital SCA and used these variables to build an SCA prediction score, which we validated internally and externally.
Results:
In the overall STEMI population (n=8112; median age, 60 years; 78% male), SCA occurred in 452 patients (5.6%). In multivariate analysis, younger age, absence of obesity, absence of diabetes mellitus, shortness of breath, and a short delay between pain onset and call to emergency medical services were the main predictors of SCA. A score built from these variables predicted SCA, with the risk increasing 2-fold in patients with a score between 10 and 19, 4-fold in those with a score between 20 and 29, and >18-fold in patients with a score ≥30 compared with those with scores <10. The SCA rate was 28.9% in patients with a score ≥30 compared with 1.6% in patients with a score ≤9 (
P
for trend <0.001). The area under the curve values were 0.7033 in the internal validation sample and 0.6031 in the external validation sample. Sensitivity and specificity varied between 96.9% and 10.5% for scores ≥10 and between 18.0% and 97.6% for scores ≥30, with scores between 20 and 29 achieving the best sensitivity and specificity (65.4% and 62.6%, respectively).
Conclusions:
At the early phase of STEMI, the risk of prehospital SCA can be determined through a simple score of 5 routinely assessed predictors. This score might help optimize the dispatching and management of patients with STEMI by emergency medical services.
Collapse
Affiliation(s)
- Nicole Karam
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Sophie Bataille
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Eloi Marijon
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Olivier Giovannetti
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Muriel Tafflet
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Dominique Savary
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Hakim Benamer
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Christophe Caussin
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Philippe Garot
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Jean-Michel Juliard
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Virginie Pires
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Thévy Boche
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - François Dupas
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Gaelle Le Bail
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Lionel Lamhaut
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - François Laborne
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Hugues Lefort
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Mireille Mapouata
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Frederic Lapostolle
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Christian Spaulding
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Jean-Philippe Empana
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Xavier Jouven
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| | - Yves Lambert
- From Sudden Death Expertise Center, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (N.K., E.M., M.T., C.S., J.-P.E., X.J.); Cardiology Department, European Georges Pompidou Hospital–APHP, Paris, France (N.K., E.M., C.S., X.J.); Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France (N.K., E.M., O.G., M.T., M.M., C.S., J.-P.E., X.J.); Regional Health Agency of Ile-de-France, Paris, France (S.B.); Emergency Department
| |
Collapse
|
19
|
Abbas M, Jesel L, Auger C, Amoura L, Messas N, Manin G, Rumig C, León-González AJ, Ribeiro TP, Silva GC, Abou-Merhi R, Hamade E, Hecker M, Georg Y, Chakfe N, Ohlmann P, Schini-Kerth VB, Toti F, Morel O. Endothelial Microparticles From Acute Coronary Syndrome Patients Induce Premature Coronary Artery Endothelial Cell Aging and Thrombogenicity: Role of the Ang II/AT1 Receptor/NADPH Oxidase-Mediated Activation of MAPKs and PI3-Kinase Pathways. Circulation 2016; 135:280-296. [PMID: 27821539 DOI: 10.1161/circulationaha.116.017513] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 10/19/2016] [Indexed: 01/01/2023]
Abstract
BACKGROUND Microparticles (MPs) have emerged as a surrogate marker of endothelial dysfunction and cardiovascular risk. This study examined the potential of MPs from senescent endothelial cells (ECs) or from patients with acute coronary syndrome (ACS) to promote premature EC aging and thrombogenicity. METHODS Primary porcine coronary ECs were isolated from the left circumflex coronary artery. MPs were prepared from ECs and venous blood from patients with ACS (n=30) and from healthy volunteers (n=4) by sequential centrifugation. The level of endothelial senescence was assessed as senescence-associated β-galactosidase activity using flow cytometry, oxidative stress using the redox-sensitive probe dihydroethidium, tissue factor activity using an enzymatic Tenase assay, the level of target protein expression by Western blot analysis, platelet aggregation using an aggregometer, and shear stress using a cone-and-plate viscometer. RESULTS Senescence, as assessed by senescence-associated β-galactosidase activity, was induced by the passaging of porcine coronary artery ECs from passage P1 to P4, and was associated with a progressive shedding of procoagulant MPs. Exposure of P1 ECs to MPs shed from senescent P3 cells or circulating MPs from ACS patients induced increased senescence-associated β-galactosidase activity, oxidative stress, early phosphorylation of mitogen-activated protein kinases and Akt, and upregulation of p53, p21, and p16. Ex vivo, the prosenescent effect of circulating MPs from ACS patients was evidenced only under conditions of low shear stress. Depletion of endothelial-derived MPs from ACS patients reduced the induction of senescence. Prosenescent MPs promoted EC thrombogenicity through tissue factor upregulation, shedding of procoagulant MPs, endothelial nitric oxide synthase downregulation, and reduced nitric oxide-mediated inhibition of platelet aggregation. These MPs exhibited angiotensin-converting enzyme activity and upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs. Losartan, an AT1 receptor antagonist, and inhibitors of either mitogen-activated protein kinases or phosphoinositide 3-kinase prevented the MP-induced endothelial senescence. CONCLUSIONS These findings indicate that endothelial-derived MPs from ACS patients induce premature endothelial senescence under atheroprone low shear stress and thrombogenicity through angiotensin II-induced redox-sensitive activation of mitogen-activated protein kinases and phosphoinositide 3-kinase/Akt. They further suggest that targeting endothelial-derived MP shedding and their bioactivity may be a promising therapeutic strategy to limit the development of an endothelial dysfunction post-ACS.
Collapse
Affiliation(s)
- Malak Abbas
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Laurence Jesel
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Cyril Auger
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Lamia Amoura
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Nathan Messas
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Guillaume Manin
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Cordula Rumig
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Antonio J León-González
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Thais P Ribeiro
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Grazielle C Silva
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Raghida Abou-Merhi
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Eva Hamade
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Markus Hecker
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Yannick Georg
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Nabil Chakfe
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Patrick Ohlmann
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Valérie B Schini-Kerth
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Florence Toti
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Olivier Morel
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.).
| |
Collapse
|
20
|
Thulin Å, Christersson C, Alfredsson J, Siegbahn A. Circulating cell-derived microparticles as biomarkers in cardiovascular disease. Biomark Med 2016; 10:1009-22. [PMID: 27586235 DOI: 10.2217/bmm-2016-0035] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Cardiovascular diseases (CVDs) are a common cause of death, and a search for biomarkers for risk stratification is warranted. Elevated levels of cell-derived microparticles (MPs) are found in patients with CVD and in groups with risk factors for CVD. Subpopulations of MPs are promising biomarkers for improving risk prediction, as well as monitoring treatment. However, the field has been hampered by technical difficulties, and the ongoing development of sensitive standardized techniques is crucial for implementing MP analyses in the clinic. Large prospective studies are required to establish which MPs are of prognostic value in different patient groups. In this review, we discuss methodological challenges and progress in the field, as well as MP populations that are of interest for further clinical evaluation.
Collapse
Affiliation(s)
- Åsa Thulin
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden
| | | | - Jenny Alfredsson
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden
| | - Agneta Siegbahn
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden
| |
Collapse
|
21
|
Hartopo AB, Puspitawati I, Gharini PPR, Setianto BY. Platelet microparticle number is associated with the extent of myocardial damage in acute myocardial infarction. Arch Med Sci 2016; 12:529-37. [PMID: 27279844 PMCID: PMC4889687 DOI: 10.5114/aoms.2016.59926] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 09/07/2014] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Activated platelets generate microparticles. Increased platelet microparticles occur in acute myocardial infarction (AMI) and contribute to intracoronary thrombosis and subsequent myocardial injury. This study aimed to investigate the impact of platelet microparticles on intracoronary thrombosis by assessing the relationship between platelet microparticles and the extent of myocardial damage in AMI. MATERIAL AND METHODS This was a cross sectional study. The subjects were patients with acute coronary syndrome (ACS). Forty-one consecutive subjects with ACS admitted to intensive cardiovascular care unit were enrolled. The clinical spectrum of ACS comprised AMI (n = 26), both ST-elevation AMI (STEMI) and non-ST-elevation AMI (NSTEMI), and unstable angina (n = 15). Platelet microparticles were isolated from peripheral venous blood and detected with anti-CD42b-PE by the flow cytometry method. The extent of myocardial damage was determined by measuring the peak level of serial cardiac enzymes within 24 h of admission. RESULTS Subjects with AMI had a significantly higher number of platelet microparticles than those with unstable angina (4855 ±4509/µl vs. 2181 ±1923/µl respectively; p = 0.036). Subjects with STEMI had the highest number of platelet microparticles, but no significant difference was detected as compared to those with NSTEMI (5775 ±5680/µl vs. 3601 ±1632/µl). The number of platelet microparticles in AMI was positively associated with the extent of myocardial damage (peak CK-MB: r = 0.408, p = 0.019 and peak GOT: r = 0.384, p = 0.026). CONCLUSIONS The number of platelet microparticles was increased in AMI as compared to unstable angina and associated with the extent of myocardial damage.
Collapse
Affiliation(s)
- Anggoro Budi Hartopo
- Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesia
| | - Ira Puspitawati
- Department of Clinical Pathology, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesia
| | - Putrika Prastuti Ratna Gharini
- Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesia
| | - Budi Yuli Setianto
- Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesia
| |
Collapse
|
22
|
Sun C, Zhao WB, Chen Y, Hu HY. Higher Plasma Concentrations of Platelet Microparticles in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-analysis. Can J Cardiol 2016; 32:1325.e1-1325.e10. [PMID: 27177836 DOI: 10.1016/j.cjca.2016.02.052] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 02/02/2016] [Accepted: 02/07/2016] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Platelet microparticles (PMP), shedding on platelet activation, have been proposed as key components in the procoagulant and proinflammatory process. The aim of this study was to clarify the correlation between plasma PMP concentration and the presence of acute coronary syndrome (ACS). METHODS We searched for potential relevant studies in PubMed, EMBASE, the Cochrane Library, and Web of Science databases before December 2015. After screening for eligibility, 11 observational studies that tested the plasma concentration of PMP in patients with ACS were retrieved for comprehensive review, quality assessment, and data extraction. RESULTS Seven studies (64%) provided explicit information between healthy controls and patients with ACS. Five studies (45%) addressed the plasma levels of PMP between patients with ACS and patients with stable angina. Moreover, 5 studies (45%) compared changes in PMP concentration before and after percutaneous coronary intervention (PCI) in patients with ACS. The results showed a significant difference in plasma PMP levels between the patients with ACS and healthy controls, with the pooled standardized mean difference of 1.95 (95% confidence intervals, 0.87-3.02; P < 0.0001). And the plasma concentration of PMP in patients with ACS was higher before PCI than after PCI (standardized mean difference, -0.97; 95% confidence interval, -1.91 to -0.03; P = 0.043). Four of the five studies described that patients with ACS had higher plasma PMP concentration than patients with stable angina, but there was no significant difference between these 2 patient cohorts. CONCLUSIONS PMP is a promising biomarker for the development of ACS. Moreover, PCI, the most common treatment for ACS, could effectively decrease the plasma concentration of PMP, indicating PMP as a prognostic factor.
Collapse
Affiliation(s)
- Cheng Sun
- Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Wei-Bo Zhao
- Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Yan Chen
- Department of Anesthesiology, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Hou-Yuan Hu
- Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, China.
| |
Collapse
|
23
|
Zhou B, Li J, Chen S, Zhou E, Zheng L, Zu L, Gao W. Time course of various cell origin circulating microparticles in ST-segment elevation myocardial infarction patients undergoing percutaneous transluminal coronary intervention. Exp Ther Med 2016; 11:1481-1486. [PMID: 27073469 DOI: 10.3892/etm.2016.3060] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 01/15/2016] [Indexed: 12/12/2022] Open
Abstract
The present study aimed to investigate the time course of changes in microparticles (MPs) in patients with ST-segment elevation myocardial infarction (STEMI) that underwent percutaneous transluminal coronary intervention (PCI). A total of 24 STEMI patients undergoing primary PCI were enrolled, and circulating MPs were detected immediately prior to and after PCI, and at 4, 24 and 48 h post-PCI. Standard Megamix beads, based measurement protocols, were employed to measure MPs of different cell origin, including endothelial MPs (EMPs), platelet MPs (PMPs) and leukocyte-derived MPs (LMPs), which were identified by CD144, CD41 and CD45, respectively. The results indicated that PMP levels were evidently elevated immediately after PCI, and reached a maximum level at 48 h. In addition, LMP and EMP levels were significantly decreased immediately after the PCI, and then increased gradually with time. The total quantity of the three aforementioned MP types increased gradually at 48 h following PCI. Furthermore, coronary angiographic Gensini scores were significantly positively correlated with the level of PMPs (r2=0.42; P=0.0006). Log-normalized high sensitivity-C-reactive-protein was also significantly correlated with LMPs (r2=0.86; P<0.01). In conclusion, the time course of the changes in circulating MPs of different cell origin, provided information on possible functions of different MPs in STEMI.
Collapse
Affiliation(s)
- Boda Zhou
- Department of Cardiovascular Medicine, Peking University Third Hospital, Beijing 100191, P.R. China
| | - Jizhao Li
- Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Peking University Health Science Center, Beijing 100191, P.R. China
| | - Shaomin Chen
- Department of Cardiovascular Medicine, Peking University Third Hospital, Beijing 100191, P.R. China
| | - Enchen Zhou
- Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Peking University Health Science Center, Beijing 100191, P.R. China
| | - Lemin Zheng
- Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Peking University Health Science Center, Beijing 100191, P.R. China
| | - Lingyun Zu
- Department of Cardiovascular Medicine, Peking University Third Hospital, Beijing 100191, P.R. China
| | - Wei Gao
- Department of Cardiovascular Medicine, Peking University Third Hospital, Beijing 100191, P.R. China
| |
Collapse
|
24
|
Suades R, Padró T, Crespo J, Ramaiola I, Martin-Yuste V, Sabaté M, Sans-Roselló J, Sionis A, Badimon L. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. Int J Cardiol 2016; 202:378-87. [DOI: 10.1016/j.ijcard.2015.09.011] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Revised: 07/29/2015] [Accepted: 09/08/2015] [Indexed: 01/25/2023]
|
25
|
Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA. Pattern of circulating endothelial-derived microparticles among chronic heart failure patients with dysmetabolic comorbidities: The impact of subclinical hypothyroidism. Diabetes Metab Syndr 2016; 10:29-36. [PMID: 26319410 DOI: 10.1016/j.dsx.2015.08.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
UNLABELLED The study aim was to evaluate the impact of dysmetabolic comorbidities including subclinical hypothyroidism (SH) on pattern of circulating endothelial-derived microparticles (EMPs) in chronic heart failure (CHF) patients. METHODS It was retrospectively involved a cohort of 388 patients with CHF. Fifty three CHF subjects had SH and 335 patients were free from thyroid dysfunction. Circulating levels of NT-pro brain natriuretic peptide (NT-pro-BNP), high-sensitivity C-reactive protein (hs-CRP), thyroid stimulating hormone (TSH), total and free thyroxine (T4) and triiodothyronine (T3) EMPs were measured at baseline. SH was defined per contemporary clinical guideline as state associated with elevated level of serum TSH>10 μU/L and basal normal free T3 and T4 concentration. RESULTS Circulating CD31+/annexin V+ EMPs were higher in SH patients compared with none SH subjects. In contrast, activated CD62E+ EMP numbers were not significantly different between both patient cohorts. Using C-statistics for Models with TSH, New York Heart Association (NYHA) class, dyslipidemia, and circulating biomarkers (hs-CRP, NT-proBNP, serum uric acid) as Continuous Variables we found that adding of NYHA class alone, NT-proBNP alone or their combination to the based model (TSH) improved the relative integrated discrimination improvement (IDI) for increased CD31+/annexin V+ to CD62E+ ratio by 4.9%; 9.2% and 9.6% respectively. NT-proBNP improves significantly predictive model based on TSH for increased CD31+/annexin V+ to CD62E+ ratio. Among patient study population for category-free net reclassification improvement (NRI), 4% of events (P=0.026) and 6% of non-events (P=0.012) were correctly reclassified by the addition of circulating NT-proBNP to the base model (TSH) for Increased CD31+/annexin V+ to CD62E+ ratio. Therefore, 4% of events (P=0.028) and 5% of non-events (P=0.014) were correctly reclassified using category-free NRI for increased CD31+/annexin V+ to CD62E+ ratio. CONCLUSION We found that SH state in CHF patients associates with impaired pattern of circulating EMPs with predominantly increased number of apoptotic-derived microparticles.
Collapse
Affiliation(s)
- Alexander E Berezin
- Cardiology Unit, Internal Medicine Department, State Medical University, 26, Mayakovsky av., Zaporozhye, UA-69035, Ukraine.
| | - Alexander A Kremzer
- Clinical Pharmacology Department, State Medical University, Zaporozhye, Ukraine
| | | | - Tatyana A Samura
- Clinical Pharmacology Department, State Medical University, Zaporozhye, Ukraine
| | | |
Collapse
|
26
|
High Level of Endotoxemia Following Out-of-Hospital Cardiac Arrest Is Associated With Severity and Duration of Postcardiac Arrest Shock*. Crit Care Med 2015; 43:2597-604. [DOI: 10.1097/ccm.0000000000001303] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
27
|
Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA. The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients. Res Cardiovasc Med 2015; 4:e29094. [PMID: 26528453 PMCID: PMC4623383 DOI: 10.5812/cardiovascmed.29094] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 05/09/2015] [Accepted: 06/07/2015] [Indexed: 12/28/2022] Open
Abstract
Background: Subclinical hypothyroidism (SH) is diagnosed biochemically by the presence of normal serum free thyroxine concentration, in conjunction with an elevated serum thyroid-stimulating hormone level. Recent studies have demonstrated the frequent association between SH and cardiovascular diseases and risk factors. Objectives: To evaluate the impact of SH on patterns of circulating endothelial-derived microparticles, (EMPs) among chronic heart failure (CHF) patients Patients and Methods: This is a retrospective study involving a cohort of 388 patients with CHF. Fifty-three CHF subjects had SH and 335 patients were free from thyroid dysfunction. Circulating levels of N-terminal-pro brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), thyroid-stimulating hormone (TSH), total and free thyroxine (T4), and triiodothyronine (T3), and endothelial apoptotic microparticles (EMPs), were measured at baseline. SH was defined, according to contemporary clinical guidelines, as a biochemical state associated with an elevated serum TSH level of greater 10 μU/L and normal basal free T3 and T4 concentrations. Results: Circulating CD31+/annexin V+ EMPs were higher in patients with SH compared to those without SH. In contrast, activated CD62E+ EMP numbers were not significantly different between both patient cohorts. Using uni (bi) variate and multivariate age- and gender-adjusted regression analysis, we found several predictors that affected the increase of the CD31+/annexin V+ to CD62E+ ratio in the patient study population. The independent impact of TSH per 6.5 μU/L (odds ratio [OR] = 1.23, P = 0.001), SH (OR = 1.22, P = 0.001), NT-proBNP (OR = 1.19, P = 0.001), NYHA class (OR = 1.09, P = 0.001), hs-CRP per 4.50 mg/L (OR = 1.05, P = 0.001), dyslipidemia (OR = 1.06, P = 0.001), serum uric acid per 9.5 mmol/L (OR = 1.04, P = 0.022) on the increase in the CD31+/annexin V+ to CD62E+ ratio, was determined. Conclusions: We believe that the SH state in CHF patients may be associated with the impaired pattern of circulating EMPs, with the predominantly increased number of apoptotic-derived microparticles.
Collapse
Affiliation(s)
- Alexander E. Berezin
- Consultant of Therapeutic Unit, Internal Medicine Department, State Medical University, Zaporozhye, Ukraine
- Corresponding author: Alexander E. Berezin, Consultant of Therapeutic Unit, Internal Medicine Department, State Medical University, Zaporozhye, Ukraine. Tel: +38-0612894585, E-mail:
| | | | | | - Tatyana A. Samura
- Clinical Pharmacology Department, State Medical University, Zaporozhye, Ukraine
| | | |
Collapse
|
28
|
Belting M, Christianson HC. Role of exosomes and microvesicles in hypoxia-associated tumour development and cardiovascular disease. J Intern Med 2015; 278:251-63. [PMID: 26153525 DOI: 10.1111/joim.12393] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Exosomes and microvesicles, collectively referred to as extracellular vesicles (EVs), can transfer complex biological information and induce a diverse signalling response in recipient cells with potential relevance in a wide array of pathological conditions. Tissue hypoxia constitutes a stress-associated phenotype that is central to the malignant state of aggressive tumours as well as to ischaemic tissue in cardiovascular disorders. The adaptive response to hypoxic stress is largely dependent on intercellular communication in which EVs, and cellular exchange of EV cargo molecules, have recently been implicated. The results of numerous studies indicate that hypoxia-dependent shaping of the molecular profile of EVs may mediate the biological response to hypoxia. EVs have been shown to induce tumour angiogenesis and hypercoagulation as well as tissue remodelling and protective effects in ischaemic cardiovascular conditions. Recent findings report increased levels of circulating EVs in patients with hypoxia-associated disorders such as myocardial infarction, stroke and pre-eclampsia, indicating a role of EVs as biomarkers in these pathophysiological states. Here, we discuss the intriguing role of EVs in tumour development and cardiovascular disease, focusing on the paracrine transfer of the hypoxic response to neighbouring cells and to distant cells at the systemic level, with wide implications for biomarker discovery and therapeutic intervention.
Collapse
Affiliation(s)
- M Belting
- Section of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.,Department of Oncology, Skåne University Hospital, Lund, Sweden
| | - H C Christianson
- Section of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
| |
Collapse
|
29
|
Zhou BD, Guo G, Zheng LM, Zu LY, Gao W. Microparticles as novel biomarkers and therapeutic targets in coronary heart disease. Chin Med J (Engl) 2015; 128:267-72. [PMID: 25591573 PMCID: PMC4837849 DOI: 10.4103/0366-6999.149231] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Affiliation(s)
| | | | | | - Ling-Yun Zu
- Department of Cardiology, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Peking University Third Hospital, Beijing 100191, China
| | | |
Collapse
|
30
|
Jansen F, Yang X, Baumann K, Przybilla D, Schmitz T, Flender A, Paul K, Alhusseiny A, Nickenig G, Werner N. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. J Cell Mol Med 2015; 19:2202-14. [PMID: 26081516 PMCID: PMC4568925 DOI: 10.1111/jcmm.12607] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Accepted: 04/06/2015] [Indexed: 01/12/2023] Open
Abstract
Endothelial microparticles (EMP) are released from activated or apoptotic endothelial cells (ECs) and can be taken up by adjacent ECs, but their effect on vascular inflammation after engulfment is largely unknown. We sought to determine the role of EMP in EC inflammation. In vitro, EMP treatment significantly reduced tumour necrosis factor-α-induced endothelial intercellular adhesion molecule (ICAM)-1 expression on mRNA and protein level, whereas there was no effect on vascular cell adhesion molecule-1 expression. Reduced ICAM-1 expression after EMP treatment resulted in diminished monocyte adhesion in vitro. In vivo, systemic treatment of ApoE−/− mice with EMP significantly reduced murine endothelial ICAM-1 expression. To explore the underlying mechanisms, Taqman microRNA array was performed and microRNA (miR)-222 was identified as the strongest regulated miR between EMP and ECs. Following experiments demonstrated that miR-222 was transported into recipient ECs by EMP and functionally regulated expression of its target protein ICAM-1 in vitro and in vivo. After simulating diabetic conditions, EMP derived from glucose-treated ECs contained significantly lower amounts of miR-222 and showed reduced anti-inflammatory capacity in vitro and in vivo. Finally, circulating miR-222 level was diminished in patients with coronary artery disease (CAD) compared to patients without CAD. EMPs promote anti-inflammatory effects in vitro and in vivo by reducing endothelial ICAM-1 expression via the transfer of functional miR-222 into recipient cells. In pathological hyperglycaemic conditions, EMP-mediated miR-222-dependent anti-inflammatory effects are reduced.
Collapse
Affiliation(s)
- Felix Jansen
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Xiaoyan Yang
- Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine, Chicago, IL, USA
| | - Katharina Baumann
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - David Przybilla
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Theresa Schmitz
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Anna Flender
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Kathrin Paul
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Adil Alhusseiny
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Georg Nickenig
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| | - Nikos Werner
- Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany
| |
Collapse
|
31
|
Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM, Caligiuri G, Dimmeler S, Egido J, Evans PC, Guzik T, Kwak BR, Landmesser U, Mayr M, Monaco C, Pasterkamp G, Tuñón J, Weber C. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J 2015; 36:2635-42. [DOI: 10.1093/eurheartj/ehv236] [Citation(s) in RCA: 140] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 05/18/2015] [Indexed: 01/21/2023] Open
|
32
|
Horn P, Baars T, Kahlert P, Heiss C, Westenfeld R, Kelm M, Erbel R, Heusch G, Kleinbongard P. Release of Intracoronary Microparticles during Stent Implantation into Stable Atherosclerotic Lesions under Protection with an Aspiration Device. PLoS One 2015; 10:e0124904. [PMID: 25915510 PMCID: PMC4411166 DOI: 10.1371/journal.pone.0124904] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Accepted: 03/06/2015] [Indexed: 01/21/2023] Open
Abstract
OBJECTIVE Stent implantation into atherosclerotic coronary vessels impacts on downstream microvascular function and induces the release of particulate debris and soluble substances, which differs qualitatively and quantitatively between native right coronary arteries (RCAs) and saphenous vein grafts on right coronary arteries (SVG-RCAs). We have now quantified the release of microparticles (MPs) during stent implantation into stable atherosclerotic lesions and compared the release between RCAs and SVG-RCAs. METHODS In symptomatic, male patients with stable angina and a stenosis in their RCA or SVG-RCA, respectively (n = 14/14), plaque volume and composition were analyzed using intravascular ultrasound before stent implantation. Coronary aspirate was retrieved during stent implantation with a distal occlusion/aspiration device and divided into particulate debris and plasma. Particulate debris was weighed. Platelet-derived MPs (PMPs) were distinguished by flow cytometry as CD41+, endothelium-derived MPs (EMPs) as CD144+, CD62E+ and CD31+/CD41-, leukocyte-derived MPs as CD45+, and erythrocyte-derived MPs as CD235+. RESULTS In patients with comparable plaque volume and composition in RCAs and SVG-RCAs, intracoronary PMPs and EMPs were increased after stent implantation into their RCAs and SVG-RCAs (CD41+: 2729.6 ± 645.6 vs. 4208.7 ± 679.4 and 2355.9 ± 503.9 vs. 3285.8 ± 733.2 nr/µL; CD144+: 451.5 ± 87.9 vs. 861.7 ± 147.0 and 444.6 ± 74.8 vs. 726.5 ± 136.4 nr/µL; CD62E+: 1404.1 ± 247.7 vs. 1844.3 ± 378.6 and 1084.6 ± 211.0 vs. 1783.8 ± 384.3 nr/µL, P < 0.05), but not different between RCAs and SVG-RCAs. CONCLUSION Stenting in stable atherosclerotic lesions is associated with a substantial release not only of PMPs, but also of EMPs in RCAs and SVG-RCAs. Their release does not differ between RCAs and SVG-RCAs. TRIAL REGISTRATION ClinicalTrials.gov NCT01430884.
Collapse
Affiliation(s)
- Patrick Horn
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany
| | - Theodor Baars
- Institute for Pathophysiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Essen, Germany
- Clinic for Cardiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Essen, Germany
| | - Philipp Kahlert
- Clinic for Cardiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Essen, Germany
| | - Christian Heiss
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany
| | - Ralf Westenfeld
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany
| | - Malte Kelm
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany
| | - Raimund Erbel
- Clinic for Cardiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Essen, Germany
| | - Gerd Heusch
- Institute for Pathophysiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Essen, Germany
| | - Petra Kleinbongard
- Institute for Pathophysiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Essen, Germany
- * E-mail:
| |
Collapse
|
33
|
Fink K, Moebes M, Vetter C, Bourgeois N, Schmid B, Bode C, Helbing T, Busch HJ. Selenium prevents microparticle-induced endothelial inflammation in patients after cardiopulmonary resuscitation. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2015; 19:58. [PMID: 25886988 PMCID: PMC4367830 DOI: 10.1186/s13054-015-0774-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Accepted: 01/23/2015] [Indexed: 02/04/2023]
Abstract
Introduction Microparticles are elevated in patients after successful cardiopulmonary resuscitation (CPR) and may play a role in the development of endothelial dysfunction seen in post-cardiac arrest syndrome (PCAS), a life threatening disease with high mortality. To identify mechanisms of endothelial activation and to develop novel approaches in the therapy of PCAS, the impact of selenium, a trace element with antioxidative properties, was characterized in endothelial dysfunction induced by microparticles of resuscitated patients. Additionally, course of plasma selenium levels was characterized in the first 72 hours post-CPR. Methods Endothelial cells were exposed to microparticles isolated of the peripheral blood of resuscitated patients, and leukocyte-endothelial interaction was measured by dynamic adhesion assay. Expression of adhesion molecules was assessed by immunoblotting and flow chamber. Blood samples were drawn 24, 48 and 72 hours after CPR for determination of plasma selenium levels in 77 resuscitated patients; these were compared to 50 healthy subjects and 50 patients with stable cardiac disease and correlated with severity of illness and outcome. Results Microparticles of resuscitated patients enhance monocyte-endothelial interaction by up-regulation of ICAM-1 and VCAM-1. Selenium administration diminished ICAM-1 and VCAM-1-mediated monocyte adhesion induced by microparticles of resuscitated patients, suggesting that selenium has anti-inflammatory effects after CPR. Lowered selenium plasma levels were observed in resuscitated patients compared to controls and selenium levels immediately and 24 hours after CPR, inversely correlated with clinical course and outcome after resuscitation. Conclusions Endothelial dysfunction is a pivotal feature of PCAS and is partly driven by microparticles of resuscitated patients. Administration of selenium exerted anti-inflammatory effects and prevented microparticle-mediated endothelial dysfunction. Decline of selenium was observed in plasma of patients after CPR and is a novel predictive marker of ICU mortality, suggesting selenium consumption promotes inflammation in PCAS. Electronic supplementary material The online version of this article (doi:10.1186/s13054-015-0774-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Katrin Fink
- Department of Emergency Medicine, University hospital of Freiburg, Sir-Hans-A.-Krebs-Str., 79106, Freiburg im Breisgau, Germany.
| | - Monica Moebes
- Department of Cardiology and Angiology I, University Heart Center Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.
| | - Caroline Vetter
- Department of Cardiology and Angiology I, University Heart Center Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.
| | - Natascha Bourgeois
- Department of Cardiology and Angiology I, University Heart Center Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.
| | - Bonaventura Schmid
- Department of Emergency Medicine, University hospital of Freiburg, Sir-Hans-A.-Krebs-Str., 79106, Freiburg im Breisgau, Germany.
| | - Christoph Bode
- Department of Cardiology and Angiology I, University Heart Center Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.
| | - Thomas Helbing
- Department of Cardiology and Angiology I, University Heart Center Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.
| | - Hans-Jörg Busch
- Department of Emergency Medicine, University hospital of Freiburg, Sir-Hans-A.-Krebs-Str., 79106, Freiburg im Breisgau, Germany.
| |
Collapse
|